» Articles » PMID: 33371337

Epidemiologic Analysis of Taiwanese Patients with Idiopathic Pulmonary Fibrosis

Overview
Specialty Health Services
Date 2020 Dec 29
PMID 33371337
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Several databases of epidemiologic studies in patients with idiopathic pulmonary fibrosis (IPF) have been analyzed in the Western community. However, few studies have been reported in Asia. The objective of this study was to investigate the epidemiology of IPF in Taiwan. We collected and analyzed patients with IPF from the Taiwan National Health Insurance Research Database from 2001 to 2011. We estimated the annual incidence and cumulative prevalence of IPF and mean survival time of patients and determined the causes of death. The annual incidence rates of IPF remained stable after 2005, ranging from 0.7 to 1.3 cases per 100,000 people per year, whereas the cumulative prevalence rates increased steadily from 3.1 to 6.4 cases per 100,000 people per year during 2006-2011 based on a narrow case definition. Men older than 75 years had higher incidence compared with other age groups. The mean survival after diagnosis was 6.9 years. Old age, male sex, and respiratory hospitalization were associated with shorter survival time after diagnosis. Both the incidence and prevalence rates of IPF were lower in Taiwanese patients than Western ones. Moreover, the survival time was higher in the Asian population compared with the Western population. These results may suggest the heterogeneity of the IPF definition in different study populations and geographic locations.

Citing Articles

Real-World Experience in the Clinical Use of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Taiwan: A Post-Marketing Surveillance Study.

Kuo P, Tu C, Chen C, Kao K, Hsu J, Lin M Biomedicines. 2024; 12(10).

PMID: 39457660 PMC: 11504274. DOI: 10.3390/biomedicines12102348.


Impaired lung function and lung cancer risk in 461 183 healthy individuals: a cohort study.

Kyaw T, Tsai M, Wen C, Shu C, Su T, Wu X BMJ Open Respir Res. 2024; 11(1).

PMID: 38719501 PMC: 11086288. DOI: 10.1136/bmjresp-2023-001936.


Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000-2016 cohort.

Wang Y, Shen T, Lin C, Tu C, Hsia T, Hsu W Open Med (Wars). 2023; 18(1):20230852.

PMID: 38025536 PMC: 10655681. DOI: 10.1515/med-2023-0852.


Colchicine Is a Weapon for Managing the Heart Disease Among Interstitial Lung Disease With Viral Infection: Have We Found the Holy Grail?.

Yeh J, Hung T, Lin C, Chen T, Liw P, Yu Y Front Cardiovasc Med. 2022; 9:925211.

PMID: 35837610 PMC: 9273766. DOI: 10.3389/fcvm.2022.925211.


Hydroxychloroquine on the Pulmonary Vascular Diseases in Interstitial Lung Disease: Immunologic Effects, and Virus Interplay.

Yeh J, Syue S, Sun Y, Yeh Y, Zheng Y, Lin C Biomedicines. 2022; 10(6).

PMID: 35740313 PMC: 9219797. DOI: 10.3390/biomedicines10061290.


References
1.
Brown A, Fischer C, Shlobin O, Buhr R, Ahmad S, Weir N . Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study. Chest. 2014; 147(1):173-179. DOI: 10.1378/chest.13-2424. View

2.
Lai C, Wang C, Lu H, Chen L, Teng N, Yan Y . Idiopathic pulmonary fibrosis in Taiwan - a population-based study. Respir Med. 2012; 106(11):1566-74. DOI: 10.1016/j.rmed.2012.07.012. View

3.
Caminati A, Madotto F, Cesana G, Conti S, Harari S . Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation. Eur Respir Rev. 2015; 24(137):436-44. PMC: 9487686. DOI: 10.1183/16000617.0040-2015. View

4.
Ley B, Collard H, King Jr T . Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010; 183(4):431-40. DOI: 10.1164/rccm.201006-0894CI. View

5.
Raghu G, Weycker D, Edelsberg J, Bradford W, Oster G . Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 174(7):810-6. DOI: 10.1164/rccm.200602-163OC. View